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Pleiotropic effects of niacin: Current possibilities 
for its clinical use
Niacin was the first hypolipidemic drug to significantly re-
duce both major cardiovascular events and mortality in 
patients with cardiovascular disease. Niacin favorably in-
fluences all lipoprotein classes, including lipoprotein[a],and 
belongs to the most potent hypolipidemic drugs for in-
creasing HDL-C. Moreover, niacin causes favorable chang-
es to the qualitative composition of lipoprotein HDL. In 
addition to its pronounced hypolipidemic action, niacin 
exerts many other, non-hypolipidemic effects (e.g., antioxi-
dative, anti-inflammatory, antithrombotic), which favor-
ably influence the development and progression of athero-
sclerosis. These effects are dependent on activation of the 
specific receptor HCA2. Recent results published by the 
two large clinical studies, AIM-HIGH and HPS2-THRIVE, 
have led to the impugnation of niacin’s role in future clini-
cal practice. However, due to several methodological flaws 
in the AIM-HIGH and HPS2-THRIVE studies, the pleiotro-
pic effects of niacin now deserve thorough evaluation. This 
review summarizes the present and possible future use of 
niacin in clinical practice in light of its newly recognized 
pleiotropic effects.




Niacin (pyridine-3-carboxylic acid, nicotinic acid, vitamin B3,) was the first drug to sig-
nificantly reduce major cardiovascular events and mortality in patients with documented 
myocardial infarction, as described in the randomized, double-blind CDP (coronary drug 
project) study (1). Even nine years after termination of the trial, mortality in the niacin group 
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HDL-cholesterol level by about 15–40 %, lowers triacylglycerols (TAG) by 20–50 %, LDL-
cholesterol by 5–25 % and lipoprotein[a] (Lp[a]) by 20 % (3, 4). As regards increasing HDL-C, 
niacin is the most powerful drug of all the known lipid-lowering drugs. It has been shown 
that an increase in HDL due to niacin exceeds that of fibrate treatment approximately 1.6-
fold (5). Niacin increases the formation of HDL in the liver by stimulating phospholipids/
cholesterol efflux through transcription of the ABCA1 gene (6, 7) via the DR4-dependent 
transcription pathway (8). Moreover, as well as increasing HDL-C, niacin causes changes to 
the qualitative composition of lipoprotein HDL in that it selectively increases plasma HDL 
particles containing mainly apoA-I (LP-AI, HDL subclasses with cardio-protective proper-
ties) on the expense of HDL particles containing both apoA-I and A-II (LP-AI+AII) (9).
Lipoprotein HDL does not only increase reverse cholesterol transport (RCT) capacity 
by activating the ABCA1 transporter, but it also has additional effects: (i) anti-inflamma-
tory – HDL inhibits the expression of VCAM-1, ICAM-1 and E-selectin in the vascular wall; 
(ii) antithrombotic – HDL suppresses blood platelet aggregation, binding of fibrinogen and 
secretion of thromboxane A; (iii) pro-fibrinolytic – HDL downregulates plasminogen acti-
vator inhibitor-1 (PAI-1) and upregulates the tissue plasminogen activator (t-PA); (iv) anti-
oxidative – dependent on apolipoprotein A-I and enzymes such as paraoxonase 1, LCAT, 
glutathione selenoperoxidase (GSPx) and lipoprotein-associated phospholipase A2 (Lp-
PLA2) (for a review, see refs. 10, 11).
Interestingly, in most studies, niacin has been combined with other lipid-lowering 
drugs. In the Stockholm ischaemic heart disease secondary prevention study (12), the com-
bination of niacin with clofibrate decreased cardiovascular mortality by 36 % and total 
mortality by 26 %. In the angiographic studies CLAS (Cholesterol lowering atherosclerosis 
study) (13) and FATS (Familial atherosclerosis treatment study) (14), niacin was combined 
with colestipol: decreased progression and occasional regression of atherosclerotic lesions 
were reported along with a coincident decrease in cardiovascular events. Results from two 
large controlled studies (AIM-HIGH and HPS2-THRIVE) were published recently (15). 
HPS2-THRIVE collaborative group 2014 (16) questioned the use of niacin as a hypolipidemic 
drug. Both of these studies were multicenter (and in the case of HPS2-THRIVE also multi-
ethnic), with a large number of participants, and with primary end points covering a broad 
range of events, including nonfatal MI, CHD death, ischemic stroke, as well as hospitaliza-
tion for revascularization. Furthermore, the HPS2-THRIVE study was by far the largest 
niacin study at the time (17). It was concluded that the addition of niacin to statin treatment 
does not significantly reduce the risk of major vascular events but does increase the risk of 
serious adverse events. Nevertheless, in addition to its lipid metabolism-modifying action, 
niacin treatment is associated with multiple non-hypolipidemic effects, which favorably 
affect the development and progression of atherosclerosis and its complications.
These effects certainly warrant comprehensive evaluation, especially given the criti-
cism leveled at the methodological flaws contained in the published results of the AIM-
HIGH and HPS2-THRIVE studies (18–23). Indeed, both of these studies have serious 
drawbacks (see above): the AIM-HIGH study was underpowered, low-dose niacin was 
administered to patients in the placebo-group (18) and it suffered from selection bias (pati-
ents with triacylglycerols above 400 mg per 100 mL were excluded) (20). A relatively high-
er proportion of non-Caucasians (more than 11,000 Chinese probands, who have a higher 
risk of side-effects than other patient subgroups) were enrolled in the HPS2-THRIVE study 
(16, 22). The design of both studies ignored the pharmacokinetics of ER niacin (meal time 
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vs. bedtime dosages) (17, 20). The AIM-HIGH study was terminated prematurely; and the 
combination of niacin with laropiprant, a prostaglandin-D2 receptor antagonist, did not 
account for the adverse effects of laropiprant when administered exclusively (immune 
dysfunction, gastrointestinal bleeding, attenuation of reverse cholesterol transport) (21).
The aim of this article is to survey the pleiotropic effects of niacin on atherosclerosis, 
namely risk factors such as endothelial dysfunction, subclinical inflammation, the pro-
coagulant state, oxidative stress and the metabolic/endocrine functioning of the liver, adi-
pose tissue and pancreas. Moreover, this review summarizes the present and possible 
future niacin use in clinical practice.
MECHANISMS OF THE ANTIATHEROGENIC EFFECTS OF NIACIN
Niacin exerts most of its effects after binding to specific receptors. Niacin is an agonist 
for the G-protein-coupled receptor known as hydroxycarboxylic acid receptor 2 (HCA2, 
formerly known as GPR109A, HM74a and NIACR1) with endogenous ligand b-hydroxybu-
tyrate. Lactate is recognized as an endogenous ligand for GPR81 (HCA1 receptor) and 
3-hydroxyl-octanoic acid has been found to be a ligand for GPR109B (HCA3 receptor, 
HM74, NIACR2) (24). HCA2 is expressed in adipocytes, neutrophils, macrophages, Lang-
erhans cells and keratinocytes (Fig. 1). Activation of HCA2, a G protein-coupled membrane 
receptor, in adipocytes leads to inhibition of adenylate cyclase, decreased cAMP response, 
reduced activity of protein kinase A and decreased hormone-sensitive lipase activity, 
which in turn reduces lipolysis (24). Reduced flux of non-esterified fatty acids (NEFA) to 
the liver leads to decreased VLDL secretion. It is also connected with suppressed expres-
sion of the PPARg coactivator-1b (PGC-1b) and apolipoprotein C-III, with subsequent de-
creased secretion and increased turnover of VLDL (25). Further, in the liver, niacin en-
hances degradation of apolipoprotein B, inhibits the reuptake of HDL by inhibiting 
specific receptors (the surface-expressed ATP-synthase b-chain) (26) and non-competitive-
ly inhibits liver diacylglycerol acyltransferase-2 (DGAT 2) (27).
Activation of HCA2 in combination with niacin exerts anti-inflammatory effects in 
endothelial cells (28), adipocytes (29) and human monocytes (30), which are associated 
with reduced vascular inflammation and the anti-atheromatous effects of niacin (Fig. 1).
Niacin and endothelial dysfunction
Endothelial dysfunction (ED) is a condition characterized by an impaired ability to 
regulate vascular tonus, which results in a shift in the actions of the endothelium towards 
reduced vasodilation, a proinflammatory state and prothrombotic properties (31). More-
over, oxidative stress (OS) and systemic low-grade as well as vascular inflammation are 
closely connected with endothelial dysfunction. According to the current knowledge, ED 
is considered to be the initial phase in the development of arterial hypertension and ath-
erosclerosis (32, 33). Oxidative stress, as a consequence of enhanced generation of reactive 
oxygen and nitrogen species (RONS), is a main risk factor of ED. OS suppresses the pro-
duction of endothelial nitrogen oxide (NO) and inhibits its vasorelaxation effects.
Dyslipidemia and vascular inflammation are among the other risk factors for ED. 
Niacin has been found to improve endothelial dysfunction. Experimental studies of Ganji 
et al. (34) have shown that niacin reduces vascular OS and inflammation. The same authors 
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have found that in cultured human aortic endothelial cells (HAEC) niacin increases nico-
tinamide adenine dinucleotide phosphate (NAD(P)H), reduces glutathione (GSH) and in-
hibits angiotensin II (ANG II)-induced RONS production, low-density lipoprotein (LDL) 
oxidation, tumor necrosis factor a (TNFa)-induced NF-kB activation, vascular cell adhesion 
molecule-1 (VCAM-1), monocyte chemotactic protein-1 (MCP-1) secretion and TNFa-in-
duced monocyte adhesion to HAEC. In another study (35), in endothelial cells (HUVEC), 
niacin significantly reduced ICAM-1 (intercellular adhesion molecule 1) and PECAM-1 
(platelet/endothelial cell adhesion molecule 1) levels, and lowered the cytokine-induced 
rise in ICAM-1 and the TNFa-induced rise in PECAM-1.
Niacin, after binding to HCA2 in adipocytes, increases the secretion of adiponectin 
(36), which has an anti-inflammatory and antioxidative effect on the vascular wall and 
improves ED (37). One of the clinically pursuable surrogate markers of ED is FMD (flow-
mediated-dilation). Patients with coronary artery disease and low concentrations of HDL-
C were proven to exhibit improved FMD parameters in one study (38). On the other hand, 
in a recent meta-analysis, the FMD-improving effect of niacin reached statistical signifi-
cance only in the primary prevention of atherosclerotic cardiovascular disease, where 
improved FMD was associated with higher doses of niacin (39). In a small study on twen-
ty-six patients treated with 1500 or 2000 mg niacin for 6 weeks, there was a significant re-
duction in plasma levels of ADMA (asymmetric dimethylarginine), which causes endothe-
lial dysfunction through the competitive inhibition of NO synthase (40).
Fig. 1. Summary of the effects of nicotinic acid. The effects of niacin are mediated by its binding to the 
HCA2 receptor (formerly GPR109A; natural ligand: b-hydroxybutyrate), which is expressed on the 
surface of many cell types, or by unknown mechanisms through which niacin influences hepatocytes 
and endothelial cells.
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Niacin and oxidative stress
Transcription factor Nrf2 (nuclear erythroid 2 p45-related factor 2) and its inhibitor 
Keap 1 (Kelch-like ECH-associated protein1) are believed to play key roles in the regula-
tion of homeostatic mechanisms that influence conditions linked with higher levels of 
oxidative stress or inflammation (33). Niacin may also have a specific role in the modula-
tion of Nrf2 activity (41). For further information, see Fig. 2.
The antioxidative effects of niacin can be divided into indirect effects, accomplished 
via increased concentrations of HDL (see above), and direct effects or „lipid-independent” 
effects, which are mediated through the activation of Nrf2, as has been shown in New 
Zealand white rabbits (41). In experimental studies, niacin exerts beneficial effects on var-
ious parameters of oxidative stress. In rats with chronic renal failure, niacin has been 
shown to decrease levels of two components [p47(phox) and p22(phox)] of the NADPH 
oxidase system, which is an important source of superoxide molecules. Concomitantly in 
the same study, prothrombotic and inflammatory parameters (MCP-1, PAI-1, TGFb COX-1, 
activation of NF-κB) decreased, and the extent of proteinuria, glomerulosclerosis and tu-
bulointersticial lesions was corrected (42). In another in vitro study carried out on HAEC 
cells, niacin was proven to lower the production of reactive oxygen species (ROS) with the 
Fig. 2. HCA2 mechanisms and oxidative stress. Activation of the HCA2 receptor brings about G-
protein-dependent signaling and recruitment of b-arrestins. G-protein pathways have many effects 
on lipid metabolism. b-arrestins stabilize the IkBa complex, thereby preventing NF-kB dissociation 
and consequent inflammatory responses. In addition, some HCA2 ligands are supposed to interact 
directly with the redox state domain of the Keap1 protein, resulting in Nrf-2 translocation into the 
nucleus and upregulation of genes with ARE promoter domains.
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consequent oxidation of LDL and inhibition of VCAM-1 and MCP-1, which play an impor-
tant role in the pathogenesis of atherosclerosis (34). A recently published study has shown 
that niacin treatment of paraquat-intoxicated rats decreases serum concentrations of 8-hy-
droxy-2’-deoxyguanosine (a marker of oxidative damage of DNA) as well as levels of tissue 
malondialdehyde (MDA), which is an indicator of lipoperoxidation (43). In a clinical study 
of 17 FHC patients with lowered HDL-C levels, niacin caused expected changes in plasma 
lipid concentrations and it decreased the levels of thiobarbituric acid reactive substances, 
lipid peroxides and paraoxonase activity (44). In the group of patients treated with rosuvas-
tatin and additional ER NA, the concentrations of ox-LDL were lower than in those on 
add-on fenofibrate therapy (45). This effect was specific for rosuvastatin among other sta-
tins (simvastatin and atorvastatin).
Niacin and inflammation
Niacin has anti-inflammatory properties, which can be described according to the 
antioxidative effects as either indirect (stimulation of anti-inflammatory HDL synthesis) 
or direct. These effects stem from the activation of the receptor HCA2 in monocytes/mac-
rophages, adipose tissue and vessel endothelium. These direct anti-inflammatory effects 
of niacin have been proven in experiments carried out on double knockout mice (Ldlr-/-& 
HCA2-/-) (46). Within vessel endothelium, the expression of cytoadhesive molecules 
(VCAM-1, ICAM-1, E-selectins) is inhibited. Furthermore, in adipose tissue, niacin sup-
presses TNFa-stimulated expression and secretion of proinflammatory cytokines – MCP-
1, RANTES and the fractalkines supporting the recruitment of T-lymphocytes and macro-
phages into atherosclerotic lesions (29). In monocytes, niacin inhibits TLR-4- and 
TLR-2-induced expression as well as the secretion of TNFa, IL-6, and MCP-1 (30). In rats, 
high doses of niacin attenuated lung inflammation and improved survival during sepsis 
while simultaneously down-regulating the NF-κB pathway (47). Moreover, niacin can 
stimulate expression and secretion of adiponectin – a protein with a broad spectrum of 
anti-inflammatory and cardioprotective effects (see below) (24). In an in vitro experiment 
carried out on human umbilical vein endothelial cells (HUVEC) and macrophages, niacin 
was shown to decrease the secretion of IL-6 and TNFa and was accompanied with the 
inhibition of NF-kB (p65 and notch1) (48). Guinea pigs were fed a high-fat diet and under 
niacin administration exhibited downregulated expression of CD36 and NF-κB p65 in the 
arterial wall (30). The described anti-inflammatory changes were independent of modifi-
cations to lipid and eicosanoid concentrations (30).
Niacin administration to patients with stable CAD leads to a significant decrease in 
concentrations of high-sensitivity C-reactive protein (hs-CRP) by up to 15 % and lipopro-
tein-associated phospholipase A2 by up to 20 % (49). In patients with metabolic syndrome, 
ER niacin improved endothelial function (FMD) by 22 %, reduced hs-CRP by 20 %, and 
caused significant regression of carotid IMT in comparison with placebo (50).The baseline 
level of CRP is a strong independent predictor of the risk of future myocardial infarction, 
peripheral vascular disease, stroke and vascular death among healthy individuals without 
known vascular disease (51).
A murine experimental model of atherosclerosis was employed to examine the mech-
anisms at play in the antiatherogenic effects of niacin. Niacin-induced activation of HCA2 
receptors expressed in macrophages within atheromatous plaques brought about higher 
expression of cholesterol transporter ABCG1 with consequent efflux of cholesterol. On the 
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other hand, it inhibited MCP-1-induced recruitment of macrophages (46). Activation of 
HCA2 has been shown to induce an anti-inflammatory response in macrophages and den-
dritic cells in the colon and enables them to support differentiation of T-regulatory lym-
phocytes and IL-10-producing T cells (52). It is believed that activation of HCA2 with bu-
tyrate (which is produced by an intestinal microbiome) is a part of the mechanism by 
which the intestinal microbiome can suppress inflammatory and pro-cancerogenic pro-
cesses within the intestine. Similar effects have been ascribed to niacin administration 
within a pharmacological range (52).
Niacin in procoagulative and prothrombotic states
Niacin also attenuates cardiovascular risk due to its beneficial effects on the factors of 
coagulation and thrombolysis, some of which have been previously identified as risk fac-
tors of atherothrombotic processes. Niacin lowers the activity of coagulation factor VII, 
levels of fibrinogen, PAI-1 and the tissue factor (53–55). These factors are considered as 
independent predictors of cardiovascular disease (56–60). Niacin, as a consequence of its 
hypolipidemic effects, has been shown to reduce thrombocyte aggregation and blood vis-
cosity (55). In another study of 50 patients with hyperlipidemia, niacin diminished throm-
bocyte counts by 20 %. Concomitantly, it led to a mild increase in MPV (mean platelet 
volume), which is a risk factor for atherothrombotic events. However, there was no subse-
quent rise in PDW (platelet distribution width) – a sign of thrombocyte activation (61). The 
pre-incubation of platelets with niacin inhibits their activation via interaction with the 
activated endothelium (62).
Niacin as well as omega-3 polyunsaturated fatty acids have been shown to reduce 
levels of lipoprotein[a] (63, 64). Lipoprotein[a] is a macromolecular complex assembled 
from one particle of LDL and one glycoprotein molecule of apolipoprotein[a]. Apo[a] is 
connected to LDL by a disulphide bond. Apo[a] is structurally homologous with plas-
minogen and is accountable for specific characteristics of Lp[a]. Lp[a] has been established 
as a risk factor of cardiovascular disease (CVD) and is not dependent on plasma lipid lev-
els or other classical risk factors (65). The glycoprotein molecule of apo[a] has a strong 
structural homology to plasminogen and may account for the prothrombotic, pro-oxida-
tive, proinflammatory and antifibrinolytic properties of Lp[a], which are the mechanisms 
that play an underlying role in atherogenesis (66). The atherogenicity of Lp[a] may be, in 
part, mediated by oxidized phospholipids associated with small apo[a] isoforms (67, 68). 
Moreover, niacin exerts in vitro effects on platelet activities due to its capacity to inhibit 
their aggregation along with the accompanying stimulation of prostaglandin release 
(thromboxane B2 and prostaglandins D2 and E2) (69).
Nevertheless, more studies should be done to elucidate the mechanism of niacin ac-
tion on the Lp[a] levels in different clinical settings.
INFLUENCE OF NIACIN ON THE METABOLISM OF ADIPOSE TISSUE,  
LIVER AND PANCREAS
Effects of niacin on adiponectin levels
Niacin activation of the specific receptor HCA2 on adipocytes leads to an increase of 
adiponectin concentrations. This phenomenon has been detected only in young forms of 
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adipocytes. A natural ligand of HCA2 is beta-hydroxyl-butyrate. Differentiated adipocytes 
that do not express HCA2 receptors fail to secrete adiponectin after stimulation with nia-
cin (36). Human adiponectin is a polypeptide of 30 kDa, containing 244 amino acid resi-
dues. This polypeptide is assembled into an array of complexes composed of multimers of 
30 kDa polypeptide. Adiponectin subunits assemble into trimers [known as low molecular 
mass (LMW) complexes], hexamers [middle molecular mass (MMW)] or a more elaborate 
high molecular mass (HMW) complex composed of nine hexamers (70). The HMW form 
corresponds to the active form of adiponectin (71). Negative correlations have been found 
not only between serum adiponectin levels and the prevalence of coronary heart disease 
(CHD) (72) but also between adiponectin levels and the extensity and intensity of coronary 
lesions (73). In a prospective study, subjects with plasma adiponectin levels in the upper 
quintile were at a significantly lower risk of myocardial infarction in comparison with 
subjects in the lower quintile (odds ratio 0.39) (74). In an 18-year follow-up study, men with 
low adiponectin and low HDL-C values showed a 2.63 times (95 % CI, 1.66 to 4.15) increa-
sed incidence of diabetes mellitus type 2 and a 1.91 times (95 % CI, 1.20 to 3.04) increased 
incidence of CHD in comparison with men with high HDL-C and high adiponectin (75). 
On the other hand, some studies have found that high levels of adiponectin in patients 
with chronic heart failure (CHF) are associated with CHF severity and mortality (76–78). 
It has also been reported that the influence of niacin on HCA2 receptors in pancreatic islets 
is partially responsible for hyperglycemia. Niacin activation of HCA2 receptors in obese 
mice fed a high-fat diet has been shown to lead to partial dysfunction of pancreatic islets 
due to the induction of ROS formation and expression of PPARg and UCP2 (79).
Influence of niacin on retinol-binding protein
One of the therapeutic targets of niacin is the lowering of retinol-binding protein 4 
(RBP4) levels. RBP4 is a polypeptide of 21 kDa, which is mainly synthesized in the liver and 
adipocytes. The recognized function of RBP4 is vitamin A (retinol) transport. Elevated 
RBP4 concentrations contribute significantly to insulin resistance, as observed in obesity 
and diabetes mellitus type 2 in both rodents and humans (80, 81). Increasing serum RBP4 
induces hepatic expression of the gluconeogenic enzyme phosphoenolpyruvate carboxyki-
nase (PEPCK) and impairs insulin signaling in muscles (81). According to the results from 
the Atherosclerosis risk in community study (ARIC study), RBP4 levels may be directly 
involved in the pathogenesis of type 2 diabetes (T2DM) in women (82). Moreover, RBP4 
may be involved in the pathophysiology of hypertriacylglycerolemia in T2DM by reducing 
VLDL catabolism (83). The lowering of serum RBP4 concentrations in obese mice has been 
shown to lead to normalization of serum RBP4 levels and to improvement in insulin sen-
sitivity (81). Decreases in serum RBP4 levels occur independently of niacin activation of the 
HCA2 receptor. In experiments on mice, it was proposed that a decrease in niacin-depen-
dent RBP4 is probably a result of increased RBP4 clearance (84).
Influence of niacin on fatty acid metabolism
Chronic treatment of a hyperlipidemic mouse model with niacin resulted in upregula-
tion of genes involved in the unsaturated FA biosynthesis, mainly by Elovl6 (fatty acid 
elongase 6), Tecr (trans-2,3-enoyl-CoA reductase), and Elovl5 in gonadal white adipose 
tissue (gWAT). These changes were associated with increased release of DHA from gWAT 
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as well as increased ratio of DHA/arachidonic acid (AA) in plasma (85). It is known that 
plasma DHA/AA ratio has been shown to be a diagnostic marker for PUFA-associated 
cardiovascular health.
The study also reported a concomitant, increased ratio of DHA/AA along with elevat-
ed levels of the DHA metabolite 19,20-dihydroxy-docosapentaenoic acid (19,20-diHDPA), 
the precursor of the highly biologically active epoxy metabolite 19(20)-EpDPA. There were 
also significant correlations of both epoxy metabolites in serum.
These effects of niacin on adipose tissue and plasma PUFAs and oxylipins pose a 
potential contributing mechanism by which niacin treatment could reduce cholesterol lev-
els and CVD risk. Epoxy-metabolites of eicosapentaenoic acid (EPA) and DHA could par-
ticipate in the cardio-protective effects of PUFA n-3 and could be used as biomarkers in 
clinical studies in order to observe the influence of PUFA n-3 on the cardiovascular system 
(86). The abovementioned changes in the profiles of PUFA observed after niacin adminis-
tration in experimental models reveal other potentially antiatherogenic and antithrombo-
genic effects of niacin, which should be verified in clinical trials.
POTENTIAL NOVEL CLINICAL INDICATIONS
Impact of niacin on non-alcoholic fatty liver disease
Results of experimental studies have shown that niacin treatment could favorably 
influence the course of non-alcoholic fatty liver disease (NAFLD), and probably also affect 
its etiopathogenesis. In rats with pre-existing liver steatosis induced by a high-fat diet, 
treatment with niacin led to considerable regression of steatosis. Niacin had no effect on 
the mRNA expression of fatty acid synthesis or oxidation genes but significantly inhibited 
mRNA levels, protein expression, and activity of diacylglycerol acyltransferase 2, a key 
enzyme in triacylglycerol synthesis (87).
In a murine model of steatohepatitis, niacin dramatically ameliorated the established 
steatohepatitis and dyslipidemia. In addition, atherogenic LDL fraction disappeared in 
fasting plasma and elevations in both postprandial NEFA and triacylglycerols were sup-
pressed. Hepatic gene expression of lipogenic genes did not decrease, while expression of 
Fsp27 (fat-specific protein 27) decreased slightly (88). Fsp27 is a protein in adipocytes and 
regulates both basal and stimulated lipolysis by interacting with adipose triacylglycerol 
lipase (ATGL). FSP27-ATGL interactions play a crucial role in regulating lipolysis, triacyl-
glycerol accumulation and insulin signaling in human adipocytes (89). So far, the effect of 
niacin treatment has not been explicitly proven in patients with NAFLD.
In a small, placebo-controlled study of obese patients with NAFLD and triacylglyc-
erol levels under 3.4 mmol L-1, a 16-week course of treatment with nicotinic acid (in a dose 
titrated to 2 g daily) had no effect on hepatic triacylglycerols content (90). In contrast, a 
study of patients with NAFLD and dyslipidemia (treated with niacin in increasing doses 
of up to 2 g daily over a period of 23 weeks) showed a statistically significant decrease in 
plasma triacylglycerols as well as reduction in the liver and visceral fat content. Simultane-
ously, the importance of the DGAT2 polymorphism rs3060 was identified, given that vari-
ant DGAT2 alleles (after adjustment for other covariates) were found to be connected with 
reduced effectiveness of niacin on the liver fat content (91).
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Pleiotropic effect of niacin on chronic renal insufficiency
Niacin has a pleiotropic effect on the progression of disease in patients with chronic 
kidney disease (CKD). The main reason for morbidity and mortality in patients with CKD 
is cardiovascular disease (92, 93). The American Heart Association has recommended that 
patients with chronic impaired renal function should be classified in the highest risk 
group for developing cardiovascular events (94). High risk of CHD in persons with CKD 
is significantly affected by dyslipidemia (95).
The pathophysiology of dyslipidemia in CKD is complex. An important role is played 
by the abnormal composition and impaired clearance of triacylglycerol-rich lipoproteins 
and their remnants. This is caused by the down-regulation of lipoprotein lipase, hepatic 
lipase, the VLDL receptor, LDL receptor-related protein (LRP) and the reduction of ApoC-
II/ApoC-III ratio, as well as other disturbances involved in lipid and lipoprotein metabo-
lism (96). Increased levels of Lp[a], which is an independent risk factor of atherothrombo-
sis, have also been identified in patients with CKD (97). Hyperphosphatemia is a further 
important risk factor of cardiovascular disease in persons with CKD (98).
Chronic renal insufficiency is characterized by impaired calcium-phosphate metabolism 
involving increased concentrations of phosphorus (99). Increased concentrations of serum 
phosphorus are associated with the manifestation of subclinical atherosclerosis as well as 
with the risk of CHD manifestations, even within limits of physiological values (100). In some 
studies, it has been demonstrated that nicotinic acid can reduce serum phosphorus (101, 102) 
by inhibiting sodium-dependent phosphate co-transporters in rat small intestine (103).
A meta-analysis of CKD studies has shown that niacin, or nicotinamide, reduces se-
rum phosphorus levels and Ca-P products significantly, and that it has additive beneficial 
effects on lipid parameters (104). Niacin can contribute to the lowering of cardiovascular 
morbidity and mortality in patients with CKD as a result of its beneficial effect on both 
dyslipidemia and hyperphosphatemia. Moreover, it is the only hypolipidemic agent that 
lowers Lp[a] (105, 63, 64). Niacin has a unique favorable impact on factors affecting the rate 
of glomerular filtration decline, including number of high-density lipoprotein (HDL) par-
ticles and their function, triacylglycerol levels, oxidative stress, inflammation and endo-
thelial function. It also lowers serum phosphorus levels by reducing dietary phosphorus 
absorption in the gastrointestinal tract (106). Niacin has been observed to work best in 
patients with lipid-profile characteristics of CKD, i.e., patients with raised VLDL-TG and 
decreased HDL (107, 20). A significant reduction in proteinuria has also been identified in 
patients with CKD and hyperlipidemia treated with niacin (108).
UNWANTED EFFECTS OF NIACIN
Adverse effects of niacin are elaborated below. These effects are usually harmless but 
they can affect patient compliance. Some of them can be alleviated and there is continuing 
in terest in niacin mimetics (109) that could circumvent metabolic pathways causing these 
effects.
Flush
The most common adverse effect in persons treated with niacin seems to be skin 
flushing, since about 70 % of persons receiving niacin suffer from this symptom (110). It 
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was suggested that flushing induced by niacin after its binding to receptor HCA2 results 
from an early phase of cyclooxygenase-1 dependent formation of prostaglandin D2 (PGD2) 
and PGE2 in Langerhans cells, followed by delayed cyclooxygenase-2 dependent produc-
tion of PGE2 by keratinocytes (111). During long-term administration of niacin, tolerance 
to flushing develops rapidly in most individuals (112).
Gastrointestinal symptoms
Gastritis-like symptoms (such as nausea, abdominal pain) were found in 10–20 % of 
patients treated with IR (immediate release) nicotinic acid (6). In a small study, increased 
hydrochloric acid secretion was found in humans after 500 mg of nicotinic acid medication 
(113). Hepatotoxicity occurs predominantly at higher doses (more than 2 to 3 g per day) and 
in formulations with sustained release (SR-niacin), the metabolism of which is connected 
with production of nicotinamide and pyrimidine derivatives (114). The IR formulations of 
niacin in common therapeutic doses almost never cause serious liver injury (115).
Effect on glucose homeostasis and uric acid
Treatment with niacin may lead to increased insulin resistance in persons suffering 
from impaired glucose tolerance (116). Niacin causes insulin resistance and increases fast-
ing serum glucose by 5 %. This increase subsides with long use of niacin (117). It was sug-
gested that this effect could be related to the rebound increase in NEFA levels following 
the transient NEFA suppression induced by niacin (118), but this mechanism is question-
able in long-term use of niacin (119). It was recently found in a mouse model that long-term 
niacin treatment resulted in insulin resistance that may be in part explained by a niacin-
induced downregulation of the cAMP-degrading enzyme phosphodiesterase 3B (120) or 
modulated through activation of the islet beta-cell HCA2, which induce PPARg – uncou-
pling protein 2 pathway (121). Moreover, HCA2 seems to play a role in jejunal glucose 
transport (122), which is enhanced in T2DM. In a recent meta-analysis, niacin therapy was 
associated with a moderately increased risk of developing diabetes regardless of the back-
ground statin or combination laropiprant therapy (123).
Nevertheless, the cardiovascular benefits of niacin were independent of fasting and 1 
hour plasma glucose at baseline levels as well as after one year of therapy in the Coronary 
Drug Project (124).
Niacin can occasionally increase plasma uric acid levels by approximately 10 % due 
to competitive inhibition of tubular secretion of uric acid and induce gout in susceptible 
subjects (125). This effect may be due to interference with renal excretion of uric acid 
(126).
Other effects
Some ocular side-effects after niacin administration have been described, such as 
blurred vision, eyelid edema, proptosis, loss of eyelashes or macular edema. These symp-
toms are reversible and dose related. Most cases were found in patients in their third to 
fifth decades of life, who were treated with a higher dose (> 3 g of niacin per day). The 
mechanism of niacin’s effect on the macula is unknown (127).
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Acanthosis nigricans (128) or niacin-induced myopathy (129) belongs to other uncom-
mon adverse effects of niacin. Niacin ER monotherapy has specifically amassed consider-
able clinical trial data that do not support an increased risk for muscle adverse experi-
ences with niacin monotherapy (130).
CONCLUSIONS
Based on recent large clinical trials, niacin cannot be advocated as general adjunctive 
therapy to statins for the patients with hyperlipidemia. However, amongst those intolerant 
to statins, there are some subgroups that may benefit from niacin therapy, based on pre-
clinical data and knowledge of its pleiotropic effects. Namely, (i) patients with a high risk 
of CHD with elevated Lp[a] levels; (ii) patients with severe hypertriacylglycerolemia, espe-
cially those intolerant to fibrates, (iii) patients with dyslipidemia associated with chronic 
kidney disease, and (iv) patients with non-alcoholic liver disease. The use of niacin in these 
subpopulations warrants further investigation.
Abbreviations, acronyms, symbols. – AA – arachidonic acid, ABC – ATP cassette bind-
ing transporter, ADMA – asymmetric dimethylarginine, apoA-I – apolipoprotein A-I, ARE 
– antioxidant responsive element, ATGL – adipose triacylglycerol lipase, CAD – coronary 
artery disease, cIMT – carotid intima media thickness, CHD – coronary heart disease, CHF 
– chronic heart failure, CKD – chronic kidney disease, COX-1 – cyclooxygenase 1, cPLA2 – 
cytosolic phospholipase A2, CRP – C-reactive protein, DGAT-2 – diacylglycerol acyltransfer-
ase 2, DHA – docosahexaenoic acid, ED – endothelial dysfunction, EPA – eicosapentaenoic 
acid, ER – extended release, FA – fatty acids, FATP – fatty acid transporting protein, FCH – 
familial hypercholesterolemia, FMD – flow-mediated dilation, GPR109A – G-protein cou-
pled receptor 109A, syn. HCA2 receptor, GPx – glutathione peroxidase, GSH – glutathione, 
GSPx – glutathione selenoperoxidase, HAEC – human aortic endothelial cells, HCA2 – hy-
droxycarboxylic acid receptor 2 (formerly GPR109A), HO-1 – heme oxygenase 1, hs-CRP – 
high-sensitivity C reactive protein, HUVEC – human umbilical vein endothelial cells, 
ICAM-1 – intercellular adhesion molecule-1, IkBa – NF-kB inhibitor a, IKKb – IkBa kinase 
b, IL – interleukin, Keap1 – Kelch-like ECH-associated protein1, LCAT – lecithin:cholesterol 
acyl transferase, Lp[a] – lipoprotein[a], Lp-PLA2 – lipoprotein associated phospholipase A2, 
LDL – low density lipoproteins, MCP-1 – monocyte chemotactic protein-1, MDA – malondi-
aldehyde, NA – niacin, NAFLD – non-alcoholic fatty liver disease, NEFA – non-esterified 
fatty acids, NF-kB- nuclear factor kB, Nrf2 – nuclear erythroid 2 p45-related factor 2, PG – 
prostaglandin, OS – oxidative stress, ox-LDL – oxidatively modified LDL particles, PAI-1 – 
plasminogen activator inhibitor-1, PECAM-1 – platelet/endothelial cell adhesion molecule-1, 
PON – paraoxonase, PPARg – peroxisome proliferator activated receptor g, PUFA – polyun-
saturated fatty acids, RANTES – regulated on activation, normal T cell expressed and se-
creted chemokine (syn. CCL5), RBP4 – retinol binding protein 4, RONS – reactive oxygen and 
nitrogen species, TAG – triacylglycerols, TBARS – thiobarbituric acid reactive substances, 
TGFb – tumor growth factor b, TNFa – tumor necrosis factor a, t-PA – tissue plasminogen 
activator, T2DM – type 2 diabetes mellitus, UCP2 – uncoupling protein 2, VCAM – vascular 
cell adhesion molecule, VLDL – very low density lipoproteins.
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